Ana Virseda-Berdices, Rubén Martín-Escolano, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, David Rojo, Cristina Díez, Víctor Hontañon, Leire Pérez-Latorre, Luis Ibañez-Samaniego, Elba Llop-Herrera, Antonio Olveira, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, María Ángeles Jiménez-Sousa, the ESCORIAL Study Group
{"title":"HCV肝硬化患者DAAs治疗后与HVPG变化相关的代谢组学变化","authors":"Ana Virseda-Berdices, Rubén Martín-Escolano, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, David Rojo, Cristina Díez, Víctor Hontañon, Leire Pérez-Latorre, Luis Ibañez-Samaniego, Elba Llop-Herrera, Antonio Olveira, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, María Ángeles Jiménez-Sousa, the ESCORIAL Study Group","doi":"10.1111/liv.16204","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis. We performed a non-targeted metabolomic analysis using gas chromatography–mass spectrometry and liquid chromatography-mass spectrometry, as well as analysis of inflammation-related biomarkers using Luminex technology. The statistical analysis was performed by Generalised Linear Mixed-effects Models (GLMM), correcting for multiple testing.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We found that increases of 2,3-butanediol (AMR = 1.15; <i>q</i>-value = 0.023) and taurocholic acid (AMR = 1.06; <i>q</i>-value < 0.001) were significantly associated with increases in HVPG and inflammatory biomarker levels from before DAA therapy to one year after completion of successful HCV treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These metabolites have a potential role as indicators of portal hypertension evolution.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients\",\"authors\":\"Ana Virseda-Berdices, Rubén Martín-Escolano, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, David Rojo, Cristina Díez, Víctor Hontañon, Leire Pérez-Latorre, Luis Ibañez-Samaniego, Elba Llop-Herrera, Antonio Olveira, Amanda Fernández-Rodríguez, Coral Barbas, Salvador Resino, María Ángeles Jiménez-Sousa, the ESCORIAL Study Group\",\"doi\":\"10.1111/liv.16204\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Aims</h3>\\n \\n <p>In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis. We performed a non-targeted metabolomic analysis using gas chromatography–mass spectrometry and liquid chromatography-mass spectrometry, as well as analysis of inflammation-related biomarkers using Luminex technology. The statistical analysis was performed by Generalised Linear Mixed-effects Models (GLMM), correcting for multiple testing.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We found that increases of 2,3-butanediol (AMR = 1.15; <i>q</i>-value = 0.023) and taurocholic acid (AMR = 1.06; <i>q</i>-value < 0.001) were significantly associated with increases in HVPG and inflammatory biomarker levels from before DAA therapy to one year after completion of successful HCV treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>These metabolites have a potential role as indicators of portal hypertension evolution.</p>\\n </section>\\n </div>\",\"PeriodicalId\":18101,\"journal\":{\"name\":\"Liver International\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2024-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/liv.16204\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.16204","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients
Background and Aims
In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.
Methods
We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis. We performed a non-targeted metabolomic analysis using gas chromatography–mass spectrometry and liquid chromatography-mass spectrometry, as well as analysis of inflammation-related biomarkers using Luminex technology. The statistical analysis was performed by Generalised Linear Mixed-effects Models (GLMM), correcting for multiple testing.
Results
We found that increases of 2,3-butanediol (AMR = 1.15; q-value = 0.023) and taurocholic acid (AMR = 1.06; q-value < 0.001) were significantly associated with increases in HVPG and inflammatory biomarker levels from before DAA therapy to one year after completion of successful HCV treatment.
Conclusions
These metabolites have a potential role as indicators of portal hypertension evolution.
期刊介绍：
Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
